

Hemochromatosis mutation linked to other morbidity

January 17 2019



(HealthDay)—HFE p.C282Y homozygosity, the most common gene



mutation causing hereditary hemochromatosis (type 1), is associated with other morbidity in men and women, according to a study published online Jan. 16 in *The BMJ*.

Luke C. Pilling, from the University of Exeter in the United Kingdom, and colleagues conducted a cohort study to compare prevalent and incident morbidity and mortality between those with the *HFE* p.C282Y genetic variant and those with no p.C282Y mutations. A total of 451,243 volunteers of European descent aged 40 to 70 years were enrolled and followed for a mean of seven years.

The researchers found that by the end of follow-up, hemochromatosis was diagnosed in 21.7 percent of men and 9.8 percent of women of the 2,890 participants homozygous for p.C282Y. Compared with those with no p.C282Y mutations, p.C282Y homozygous men aged 40 to 70 years had increased prevalence of diagnosed hemochromatosis, liver disease, rheumatoid arthritis, osteoarthritis, and diabetes mellitus (odds ratios, 411.1, 4.30, 2.23, 2.01, and 1.53, respectively). During the seven-year follow-up, 15.7 and 5.0 percent of homozygous men and men with no p.C282Y mutation, respectively, had developed at least one incident-associated condition; for women, the corresponding proportions were 10.1 and 3.4 percent. Excess morbidity was modest in p.C282Y/p.H63D heterozygotes, but hemochromatosis diagnoses were more common.

"As p.C282Y-associated iron overload is preventable and partly treatable, re-examination of the many issues involved in recommending expanded early case ascertainment or screening is justified," the authors write.

More information: Abstract/Full Text

Copyright © 2019 HealthDay. All rights reserved.



Citation: Hemochromatosis mutation linked to other morbidity (2019, January 17) retrieved 16 April 2024 from

https://medicalxpress.com/news/2019-01-hemochromatosis-mutation-linked-morbidity.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.